Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383 is registered in ClinicalTrials.gov with Inotek Pharmaceuticals Corporation as lead sponsor.

NCT NCT01917383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01917383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Lead sponsor
Inotek Pharmaceuticals Corporation
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
September 30, 2014
Enrollment
101 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension (oht), primary open-angle glaucoma (poag)